Dutasteride: A dual 5-α reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia

Annals of Pharmacotherapy

Volumn 40, Issue 4, 2006, Pages 658-665

  Dolder, Christian R ^a,b,c  

^a WINGATE UNIVERSITY   (United States)

^b Carolinas Medical Center NorthEast   (United States)

^c NONE   (United States)

Author keywords

5 reductase; Androgen; Benign prostatic hyperplasia; Dutasteride; Finasteride; Prostate

Indexed keywords

ANDROSTANOLONE; CIMETIDINE; CIPROFLOXACIN; DIGOXIN; DILTIAZEM; DUTASTERIDE; FINASTERIDE; KETOCONAZOLE; PLACEBO; RITONAVIR; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TESTOSTERONE; VERAPAMIL; WARFARIN;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EAR NOSE THROAT DISEASE; EJACULATION DISORDER; ENZYME INHIBITION; GYNECOMASTIA; HEADACHE; HUMAN; IMPOTENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALAISE; MALE; MUSCULOSKELETAL PAIN; PATIENT COUNSELING; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT;

AZASTEROIDS; CHOLESTENONE 5 ALPHA-REDUCTASE; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; MALE; MEDLINE; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 33646229568     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G540     Document Type: Review

References (29)

1. Bosch JL, Hop WC, Kirkels WJ, Schroder FH. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 1995;46(3 suppl A):34-40.
2. Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1995;22:247-61.
3. Abrams P. New words for old: lower urinary tract symptoms for "prostatism." BMJ 1994;308:929-30.
4. Eckhardt MD, van Venrooij GE, van Melick HH, Boon TA. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. J Urol 2001;166:563-8.
5. Shapiro E, Lepor H. Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am 1995;22:285-90.
6. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170:530-47.
7. Lee M. Management of benign prostatic hyperplasia. In: DiPiro JT, Talbert RL, Yee GC, eds. Pharmacotherapy: a pathophysiologic approach. 6th ed. New York: McGraw Hill, 2005:1535-46.
8. Wilson JD. The role of 5α-reduction in steroid hormone physiology. Reprod Fertil Dev 2001;13:673-8.
9. Iehle C, Radmanyi F, de Medina GDS, et al. Differences in steroid 5 alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999;68:189-95.
10. Andriole G, Bruchovsky N, Chung LWK, et al. Dihydrotestosterone and the prostate: The scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004;172:1399-403.
11. Prescribing information. Avodart (dutasteride). Research Triangle Park, NC: GlaxoSmithKline, May 205.
12. Pitts WR. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer (letter). J Urol 2005;173:1433-4.
13. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
14. Roehrborn C, Andriole G, Boyle P, Hofner K. Effect of the dual 5alpha-reductase inhibitor dutasteride on endocrine parameters and prostate volume (abstract). Eur Urol Suppl 2002;1:107.
15. Evans HC, Goa KL. Dutasteride. Drugs Aging 2003;20:905-16.
16. Andriole GL, Kirby R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;44:82-8.
17. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TLJ, Roehborn C. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:488-95.
18. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004;89:2179-84.
19. O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Hofner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003;92:262-6.
20. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
21. Andriole GL, Roehborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urol 2004;64:537-43.
22. Andriole GL, Humphrey P, Ray P, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004;172:915-9.
23. Lazier CV, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Dutasteride, the dual 5α-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004;58:130-44.
24. Sandhu JS, Te AE. The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr Urol Rep 2004;5:274-9.
25. Leport H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-9.
26. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-63.
27. Bautista OM, Kusek JW, Nyberg LM, et al. Study design of the medical therapy of prostate symptoms (MTOPS) trial. Control Clin Trials 2003;24:224-43.
28. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 2003;44:461-6.
29. www.drugstore.com/pharmacy/prices (accessed 2006 Mar 10).